141 related articles for article (PubMed ID: 23720067)
21. Tyrosine kinase inhibitors may change the metastatic pattern.
Sendur MA; Aksoy S; Ozdemir NY; Zengin N
J BUON; 2013; 18(2):544. PubMed ID: 23818376
[No Abstract] [Full Text] [Related]
22. [Carcinomatous meningitis in a post-operative patient with lung adenocarcinoma for which erlotinib was effective - a case report].
Manabe M; Mitsuoka S; Umekawa K; Tanaka H; Kimura T; Yoshimura N; Takeda A; Kudoh S; Hirata K
Gan To Kagaku Ryoho; 2012 Apr; 39(4):633-5. PubMed ID: 22504691
[TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.
Kim JE; Lee DH; Choi Y; Yoon DH; Kim SW; Suh C; Lee JS
Lung Cancer; 2009 Sep; 65(3):351-4. PubMed ID: 19157632
[TBL] [Abstract][Full Text] [Related]
24. Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.
Yamanaka Y; Sekine A; Kato T; Yamakawa H; Ikeda S; Baba T; Iwasawa T; Okudela K; Ogura T
Intern Med; 2017 Nov; 56(21):2895-2898. PubMed ID: 28943548
[TBL] [Abstract][Full Text] [Related]
25. Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study.
Zhou L; He J; Xiong W; Liu Y; Xiang J; Yu Q; Liang M; Zhou X; Ding Z; Huang M; Ren L; Zhu J; Li L; Hou M; Ding L; Tan F; Lu Y
Lung Cancer; 2016 Jun; 96():93-100. PubMed ID: 27133757
[TBL] [Abstract][Full Text] [Related]
26. Erlotinib induced skin rash spares skin in previous radiotherapy field.
Mitra SS; Simcock R
J Clin Oncol; 2006 Jun; 24(16):e28-9. PubMed ID: 16735697
[No Abstract] [Full Text] [Related]
27. Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
Nonagase Y; Okamoto K; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Shimizu T; Tsurutani J; Nakagawa K
Anticancer Drugs; 2016 Mar; 27(3):251-3. PubMed ID: 26575001
[TBL] [Abstract][Full Text] [Related]
28. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
Li N; Ou W; Yang H; Liu QW; Zhang SL; Wang BX; Wang SY
Cancer; 2014 May; 120(9):1379-86. PubMed ID: 24481719
[TBL] [Abstract][Full Text] [Related]
29. Assessment of prognostic scores of brain metastases from lung adenocarcinoma with EGFR mutations.
Li H; Lian J; Jin H; Wang W; Cao J; Zhang X; Song X; Jia S; Jia H; Ren J; Han S; Yang W; Xi Y; Lan S
J Neurooncol; 2017 May; 133(1):129-135. PubMed ID: 28391386
[TBL] [Abstract][Full Text] [Related]
30. [Erlotinib and nonsmall cell lung cancer with brain metastases: a case study with a complete and prolonged response over 17 months].
Mairovitz A; Staub E; Le Floch H; Rivière F; Bonnichon A; Margery J; Vaylet F
Rev Pneumol Clin; 2009 Oct; 65(5):318-21. PubMed ID: 19878809
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer.
Zhang J; Yu J; Sun X; Meng X
Cancer Lett; 2014 Aug; 351(1):6-12. PubMed ID: 24861428
[TBL] [Abstract][Full Text] [Related]
32. Management Difficulties in a Patient with EGFR-mutation Positive Lung Adenocarcinoma and Cerebral Metastases.
Cruz P; de Lujan L; de Castro J
Arch Bronconeumol; 2017 Jan; 53(1):37-38. PubMed ID: 27712850
[No Abstract] [Full Text] [Related]
33. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
[TBL] [Abstract][Full Text] [Related]
34. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.
Russo A; Franchina T; Ricciardi GR; Picone A; Ferraro G; Zanghì M; Toscano G; Giordano A; Adamo V
Oncotarget; 2015 Sep; 6(29):26814-25. PubMed ID: 26308162
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer.
Lind JS; Lagerwaard FJ; Smit EF; Senan S
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1391-6. PubMed ID: 19289264
[TBL] [Abstract][Full Text] [Related]
36. Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy.
Chang S; Hur J; Hong YJ; Lee HJ; Kim YJ; Han K; Choi BW
AJR Am J Roentgenol; 2018 Jan; 210(1):43-51. PubMed ID: 29091002
[TBL] [Abstract][Full Text] [Related]
37. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
38. Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.
Fiala O; Pesek M; Finek J; Krakorova G; Benesova L; Minarik M
Tumori; 2014; 100(3):e70-3. PubMed ID: 25076254
[TBL] [Abstract][Full Text] [Related]
39. A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer.
McGranahan T; Nagpal S
Curr Treat Options Oncol; 2017 Apr; 18(4):22. PubMed ID: 28391420
[TBL] [Abstract][Full Text] [Related]
40. [Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].
Tang CH; Liu XQ; Gao HJ; Li JJ; Guo WF; Li XY; Wang WX; Liu B; Qu LL; Wang WW
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):143-7. PubMed ID: 20403247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]